ANN ARBOR, MI / ACCESSWIRE / August 21, 2019 / ENDRA Life Sciences Inc.(“ENDRA”) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today announced that management will participate in the following investor conferences during the month of September:
Attendees: Francois Michelon, Chief Executive Officer and David Wells, Chief Financial Officer
Thursday, September 5, 2019: One-on-one meetings only
Location: Minneapolis, MN
Attendees: Francois Michelon, Chief Executive Officer, David Wells, Chief Financial Officer and Renaud Maloberti, Chief Commercial Officer
Presentation: Monday, September 9, 2019 at 3:25pm ET
Location: New York, NY
Attendees: Francois Michelon, Chief Executive Officer, David Wells, Chief Financial Officer and Renaud Maloberti, Chief Commercial Officer
Thursday, September 12, 2019: One-on-one meetings only
Location: New York, NY
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that visualizes tissue like CT or MRI, but at 50Xlower cost, at the point of patient care. TAEUS is designed to work in concert with over one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us
Media Contact:
George MacDougall
MacDougall
Director
(781) 235-3093
endra@macbiocom.com
www.macbiocom.com
SOURCE: ENDRA Life Sciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/556857/ENDRA-Life-Sciences-to-Participate-at-Upcoming-Investor-Conferences
NDA will be primarily based on a single Phase 1 human abuse potential clinical study…
PALO ALTO, CA / ACCESSWIRE / March 27, 2024 / Bioz, Inc., a scientific research-focused…
LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…
Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors OverhaulGENEVA, SWITZERLAND / ACCESSWIRE /…
Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…
Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…